Other

Japan Science and Technology Agency

Agency of Industrial Science and Technology

Hideki Matsui

Masayuki Matsushita

Kazuhito Tomizawa

The present invention aims to solve the conventional problems by providing a peptide compound, in which when administered to a patient of immunologic disease, cardiac hypertrophy or a disease caused by NFAT activation, the period from administration to actual exhibition of effectiveness is short and there are no side effects or antigenicity. Specifically, the present invention relates to a membrane permeable NFAT inhibitory peptide comprising several consecutive arginines and a NFAT-activity inhibitory peptide sequence; a NFAT activation inhibitory agent comprising the peptide; and a immunosuppressive agent and cardiac hypertrophy suppressive agent, comprising the peptide compound as the active ingredient.

Membrane-permeable NFAT inhibitory peptide

The object of the present invention is to provide a suppressant for neuronal cell death effective for various diseases which inhibits a constitutive active forming of calcineurin and has less side effect. An inhibitor of constitutive active forming of calcineurin, more specifically a drug which inhibits cleavage of calcineurin subunit A (CaNA) by calpain. Examples thereof include peptides having the amino acid sequence of FDGATAAARKEVIRNK (SEQ No. 1) and REESESVLTLKGLTPTG (SEQ No. 2).

Growing community of inventors

Okayama-shi, Okayama, Japan

Hideki Matsui